Diagnosis and management of von Willebrand disease in Australia

Seminars in Thrombosis and Hemostasis

Volumn 37, Issue 5, 2011, Pages 542-554

  Favaloro, Emmanuel J ^a   Bonar, Roslyn ^b   Favaloro, James ^a   Koutts, Jerry ^a  

^a WESTMEAD HOSPITAL   (Australia)

^b Royal College of Pathologists of Australasia RCPA   (Australia)

Author keywords

collagen binding; DDAVP; desmopressin; diagnosis; genetic testing; von Willebrand disease; VWD

Indexed keywords

BLOOD CLOTTING FACTOR 8; COLLAGEN BINDING PROTEIN; DESMOPRESSIN; RECOMBINANT BLOOD CLOTTING FACTOR 8; RISTOCETIN; TRANEXAMIC ACID; VON WILLEBRAND FACTOR;

AUSTRALIA; BLEEDING; BLOOD TRANSFUSION; CLINICAL PRACTICE; DIAGNOSTIC TEST; DISEASE CLASSIFICATION; DISEASE REGISTRY; GENETIC SCREENING; HUMAN; LABORATORY TEST; MANAGED CARE; MOLECULAR TYPING; PHENOTYPE; PREVALENCE; PRIORITY JOURNAL; REVIEW; SEX DIFFERENCE; VON WILLEBRAND DISEASE;

AUSTRALIA; CLINICAL LABORATORY TECHNIQUES; DEAMINO ARGININE VASOPRESSIN; FACTOR VIII; GENETIC TESTING; HUMANS; MUTATION; VON WILLEBRAND DISEASES; VON WILLEBRAND FACTOR;

EID: 80053580117     PISSN: 00946176     EISSN: 10989064     Source Type: Journal    
DOI: 10.1055/s-0031-1281041     Document Type: Review

References (37)

1. Sadler JE, Budde U, Eikenboom JC et al, Working Party on von Willebrand Disease Classification. Update on the pathophysiology and classification of von Willebrand disease: a report of the Subcommittee on von Willebrand Factor. J Thromb Haemost 2006 4 10 2103-2114 (Pubitemid 44403432)
2. Favaloro EJ. von Willebrand disease: local diagnosis and management of a globally distributed bleeding disorder. Semin Thromb Hemost 2011 37 5 000-000
3. Favaloro EJ. Identification and functional characterization of von Willebrand disease. US Hematology 2009 2 1 16-23
4. Favaloro EJ. Toward a new paradigm for the identification and functional characterization of von Willebrand disease. Semin Thromb Hemost 2009 35 1 60-75
5. Favaloro EJ. An update on the von Willebrand factor collagen binding assay: 21 years of age and beyond adolescence but not yet a mature adult. Semin Thromb Hemost 2007 33 8 727-744 (Pubitemid 351158442)
6. Favaloro EJ. Rethinking the diagnosis of von Willebrand disease. Thromb Res 2011 127 Suppl 2 S17-S21
7. Favaloro EJ, Krigstein M, Koutts J, Brighton T, Lindeman R. Genetic testing for the diagnosis of von Willebrand disease: benefits and limitations. J Coag Disorders 2010 2 37-47
8. Favaloro EJ. Genetic testing for von Willebrand disease: the case against. J Thromb Haemost 2010 8 1 6-12
9. Favaloro EJ, Lippi G, Franchini M. Contemporary platelet function testing. Clin Chem Lab Med 2010 48 5 579-598
10. Favaloro EJ, Bonar R, Kershaw G et al. Reducing errors in identification of von Willebrand disease: the experience of the Royal College of Pathologists of Australasia quality assurance program. Semin Thromb Hemost 2006 32 5 505-513 (Pubitemid 44157389)
11. Favaloro EJ, Bonar R, Meiring M, Street A, Marsden K, RCPA QAP in Haematology. 2B or not 2B? Disparate discrimination of functional VWF discordance using different assay panels or methodologies may lead to success or failure in the early identification of type 2B VWD. Thromb Haemost 2007 98 2 346-358 (Pubitemid 47250238)
12. Favaloro EJ, Mohammed S, McDonald J. Validation of improved performance characteristics for the automated von Willebrand factor ristocetin cofactor activity assay. J Thromb Haemost 2010 8 12 2842-2844
13. Favaloro EJ. Evaluation of commercial von Willebrand factor collagen binding assays to assist the discrimination of types 1 and 2 von Willebrand disease. Thromb Haemost 2010 104 5 1009-1021
14. Favaloro EJ, Lippi G, Adcock DM. Preanalytical and postanalytical variables: the leading causes of diagnostic error in hemostasis? Semin Thromb Hemost 2008 34 7 612-634
15. Favaloro EJ, Thom J, Patterson D et al. Desmopressin therapy to assist the functional identification and characterisation of von Willebrand disease: differential utility from combining two (VWF:CB and VWF:RCo) von Willebrand factor activity assays? Thromb Res 2009 123 6 862-868
16. Favaloro EJ, Thom J, Patterson D et al. Potential supplementary utility of combined PFA-100 and functional von Willebrand factor testing for the laboratory assessment of desmopressin and factor concentrate therapy in von Willebrand disease. Blood Coagul Fibrinolysis 2009 20 6 475-483
17. Coleman R, Favaloro EJ, Soltani S, Keng TB. Acquired von Willebrand disease: potential contribution of the VWF:CB to the identification of functionally inhibiting auto-antibodies to von Willebrand factor. J Thromb Haemost 2006 4 9 2085-2088 (Pubitemid 44226802)
18. Meijer P, Haverkate F. An external quality assessment program for von Willebrand factor laboratory analysis: an overview from the European concerted action on thrombosis and disabilities foundation. Semin Thromb Hemost 2006 32 5 485-491 (Pubitemid 44157386)
19. Favaloro EJ. Detailed von Willebrand factor multimer analysis in patients with von Willebrand disease in the European study, molecular and clinical markers for the diagnosis and management of type 1 von Willebrand disease (MCMDM-1VWD): a rebuttal. J Thromb Haemost 2008 6 11 1999-2001, author reply 20022003
20. Facey DA, Favaloro EJ, Maxwell E, Baker R, Hertzberg MS. Type 2B von Willebrand's disease in thirteen individuals from five unrelated Australian families: phenotype and genotype correlations. Am J Hematol 2000 63 4 197-199 (Pubitemid 30165406)
21. Rodgers SE, Lerda NV, Favaloro EJ et al. Identification of von Willebrand disease type 2N (Normandy) in Australia: a cross-laboratory investigation using different methods. Am J Clin Pathol 2002 118 2 269-276 (Pubitemid 44698454)
22. Favaloro EJ, Patterson D, Denholm A et al. Differential identification of a rare form of platelet-type (pseudo-) von Willebrand disease (VWD) from Type 2B VWD using a simplified ristocetin-induced-platelet-agglutination mixing assay and confirmed by genetic analysis. Br J Haematol 2007 139 4 623-626 (Pubitemid 350043816)
23. Favaloro EJ, Mohammed S, Koutts J. Identification and prevalence of von Willebrand disease type 2N (Normandy) in Australia. Blood Coagul Fibrinolysis 2009 20 8 706-714
24. Rodgers SE, Lloyd JV, Mangos HM, Duncan EM, McRae SJ. Diagnosis and management of adult patients with von Willebrand disease in South Australia. Semin Thromb Hemost 2011 37 5 000-000
25. Federici AB, Bucciarelli P, Castaman G et al. Management of inherited von Willebrand disease in Italy: results from the retrospective study on 1234 patients. Semin Thromb Hemost 2011 37 5 000-000
26. Federici AB, Mannucci PM, Castaman G et al. Clinical and molecular predictors of thrombocytopenia and risk of bleeding in patients with von Willebrand disease type 2B: a cohort study of 67 patients. Blood 2009 113 3 526-534
27. Frontroth JP, Hepner M, Sciuccati G, Feliú Torres A, Pieroni G, Bonduel M. Prospective study of low-dose ristocetin-induced platelet aggregation to identify type 2B von Willebrand disease (VWD) and platelet-type VWD in children. Thromb Haemost 2010 104 6 1158-1165
28. Favaloro EJ. Phenotypic identification of platelet-type von Willebrand disease and its discrimination from type 2B von Willebrand disease: a question of 2B or not 2B? A story of nonidentical twins? Or two sides of a multidenominational or multifaceted primary-hemostasis coin? Semin Thromb Hemost 2008 34 1 113-127
29. Hamilton A, Ozelo M, Leggo J et al. Frequency of platelet type versus type 2B von Willebrand disease. An international registry-based study. Thromb Haemost 2011 105 3 501-508
30. Othman M. Platelet-type von Willebrand disease: a rare, often misdiagnosed and underdiagnosed bleeding disorder. Semin Thromb Hemost 2011 37 5 000-000
31. de Wee EM, Leebeek FWG, Eikenboom JCJ. Diagnosis and management of von Willebrand disease in The Netherlands. Semin Thromb Hemost 2011 37 5 000-000
32. Keeney S, Collins P, Cumming A, Goodeve A, Pasi J. Diagnosis and management of von Willebrand disease in the United Kingdom. Semin Thromb Hemost 2011 37 5 000-000
33. James PD, Lillicrap DP. The diagnosis and management of von Willebrand disease in Canada. Semin Thromb Hemost 2011 37 5 000-000
34. Favaloro EJ, Bukuya M, Martinelli T et al. A comparative multi-laboratory assessment of three factor VIII/ von Willebrand factor concentrates. Thromb Haemost 2002 87 3 466-476 (Pubitemid 34232489)
35. Favaloro EJ, Lloyd J, Rowell J et al. Comparison of the pharmacokinetics of two von Willebrand factor concentrates [Biostate and AHF (High Purity)] in people with von Willebrand disorder. A randomised cross-over, multi-centre study. Thromb Haemost 2007 97 6 922-930 (Pubitemid 46939204)
36. Shortt J, Dunkley S, Rickard K, Baker R, Street A. Efficacy and safety of a high purity, double virus inactivated factor VIII/ von Willebrand factor concentrate (Biostate) in patients with von Willebrand disorder requiring invasive or surgical procedures. Haemophilia 2007 13 2 144-148 (Pubitemid 46237945)
37. Dunkley S, Baker R.I, Pidcock M, et al. Clinical efficacy and safety of the factor VIII/ von Willebrand factor concentrate BIOSTATE in patients with von Willebrand's disease: A prospective multi-centre study. Haemophilia 2010 16 4 615-624.